A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Recruiting

Phase 3

Coagulation Factor VIIaA Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM

Sponsor:

Laboratoire français de Fractionnement et de Biotechnologies

Code:

NCT05695391

Conditions

Hemophilia

Eligibility Criteria

Sex: Male

Age: 12 - 65

Healthy Volunteers: Not accepted

Interventions

Coagulation Factor VIIa (Recombinant)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Laboratoire français de Fractionnement et de Biotechnologies on 2024-09-27.